Virtual screening: a real screening complement to high-throughput screening.

J Mestres

doi:10.1042/bst0300797

Home/Archive/PubMed

PubMed · 12196200

Virtual screening: a real screening complement to high-throughput screening.

J Mestres

View original source ↗Export metadata ↓

Abstract

Virtual screening is being routinely used as an integral part of today's hit-identification strategies for, on one hand, prioritizing large corporate screening collections and, on the other hand, to extend the scope of screening to external databases. A brief description of the essential elements required for virtual screening and an application example to the identification of agonist hits for the oestrogen receptor subtype ER alpha are presented.

Explore related subjects

Drug Evaluation, Preclinical Drug Industry Reproducibility of Results User-Computer Interface Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J Mestres. 2002. Virtual screening: a real screening complement to high-throughput screening.. https://doi.org/10.1042/bst0300797

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors.

Screening of our in-house compound collection led to the discovery of 5-bromo-6-amino-2-isoquinoline 1 as a weak inhibitor of IMPDH. Subsequent optimization of 1 afforded a series of novel 2-isoquinolinoaminooxazole-based inhibitors, represented by 17, with single-digit nanomolar potency against the enzyme.

Drug Evaluation, Preclinical↗

PubMed2003

Multiplex inhibitor screening and kinetic constant determinations for yeast hexokinase using mass spectrometry based assays.

An electrospray ionization mass spectrometry based assay was developed for kinetic measurements and inhibitor screening of yeast hexokinase. There is considerable discrepancy in the literature as to the accuracy of kinetic data obtained for hexokinase. In the assay described herein, the product, glucose 6-phosphate was directly monitored by ion trap mass spectrometry and quantified using an internal standard, 2 deoxy-glucose 6-phosphate. The kinetic parameters, K(M) and V(max) for the two substrates were determined without using a coupling enzyme as is normally employed in the traditional spectrophotometric assay for systems lacking a chromophore. In addition, hexokinase was successfully immobilized onto an amino-link gel, and a mock library was screened against the immobilized enzyme for the identification of possible inhibitors. After comparing the mass spectra of the library before and after incubation, trehalose 6-phosphate, ADP, and oxidized glutathione were differentiated from other weak or non-inhibitors. Inhibition behavior of ADP with respect to ATP was further evaluated with the ESI-MS assay and the value of K(i) was determined. This ESI-MS assay was demonstrated to be both accurate and precise for determining kinetic constants and for identifying enzyme inhibitors.

Drug Evaluation, Preclinical↗

PubMed2003

Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia.

Forward chemical genetics is a new method to systematize the discovery and use of small molecules as tools for basic biological research. This approach requires three basic components: a library of compounds; an assay, in which the library is screened for a cellular or organismal phenotype; and a method to trace an active compound to its biological target. Bioactive compounds have traditionally been isolated from natural product extracts, although 'diversity-oriented synthesis' and commercial compound collections are gaining in prominence. New techniques, such as image-based screening and the cytoblot method, have increased the throughput of phenotypic assays. Strategies are also being developed to streamline target identification using molecular biological approaches.

Drug Evaluation, Preclinical↗